

Ref: FOI/GS/ID 8269

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

23 June 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Lung cancer.

You asked:

Q1 - How many patients has your Trust treated in the past 3 months for:

- a. Non-small cell lung cancer (NSCLC) - any treatment*
- b. Non-small cell lung cancer (NSCLC) - surgical treatment*
- c. Non-small cell lung cancer (NSCLC) - radiotherapy*
- d. Non-small cell lung cancer (NSCLC) - systemic anti-cancer treatment (SACT)*

Q2 - How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)*
- b. Amivantamab*
- c. Atezolizumab monotherapy*
- d. Atezolizumab with chemotherapy*
- e. Dabrafenib + Trametinib*
- f. Durvalumab*
- g. Gemcitabine*
- h. Nitendanib + Docetaxel*
- i. Nivolumab*
- j. Osimertinib*
- k. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)*
- l. Paclitaxel*
- m. Pembrolizumab monotherapy*
- n. Pembrolizumab with chemotherapy*
- o. Pemetrexed with carboplatin/cisplatin*
- p. RET Inhibitors (Pralsetinib, Selpercatinib)*
- q. Sotorasib*

r. Tepotinib

s. Vinorelbine monotherapy or combination with Carboplatin/Cisplatin

t. Other active systemic anti-cancer therapy [please state]

u. Palliative care only

Q3 - Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab?

Trust response:

1.

a. 176

b. 0

c. 90

d. 99

2.

a. 8

b. 0

c. 2

d. 1

e. 2

f. 3

g. 0

h. 4

i. 2

j. 22

k. 5

l. 0

m. 20

n. 9

o. 5

p. 1

q. 0

r. 0

s. 10

t. 8

u. 5

Part t – Other

Carboplatin/Paclitaxel 5

Docetaxel 1

Entrectinib 1

Larotrectinib 1

3. 2